Lipid-modified muc-1 derivatives
US6600012B1 · kind B1 · utility
26Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2000 |
| Grant date | Jul 29, 2003 |
| Priority date | — |
| Expiry date | Feb 3, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for generating a mixture of activated T-cells by combining a plurality of peripheral blood lymphocytes (PBLs) with an antigen-loaded liposome to produce antigen-loaded PBLs, and combining the antigen-loaded PBLs with a naive, anergic or memory T-cell, to produce an activated T-cell. Such activation is carried out in vivo or in vitro. The antigen-loaded PBLs and activated T-cells, prepared according to the methods of invention, have use as cellular vaccines for treatment of cancer and viral diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.